Talk Radioisotopes: Going Nuclear on Cancer

In this episode of Talk Radioisotopes, Paul Schrimpf, Proprietor and Entrepreneur at Cyrall, unpacks what it takes to build and scale a radiopharmaceutical business. With a background spanning Accenture, Prophet, and leadership roles advising top healthcare organizations, Paul draws on deep experience across strategy, marketing, and team development to lay out what radiopharma innovators can learn...

In this episode of Talk Radioisotopes , host Scott Ravi sits down with Sigal Kalmanson Cusnir, CEO and Co-Founder of Starget Pharma, an early-stage company at the forefront of precision oncology. Starget is redefining the way radiopharmaceuticals are discovered and developed by merging AI technology with decades of expertise in peptide chemistry. Sigal shares how Starget's proprietary backbone cyc...

In this episode, Milton Lönnroth, Co-Founder and CEO, shares how Atley Solutions is changing the game for astatine-211, a promising isotope in cancer therapy. Atley supports radiopharmaceutical companies and researchers by enabling the scalable production and labeling of astatine-based compounds. Milton explains how the company's roots in the University of Gothenburg’s alpha therapy group shaped a...

In this episode, host Scott Larrivee speaks with Dr. Luke Nordquist, a medical oncologist and Founder/CEO of XCancer, a globally recognized clinical research center. Dr. Nordquist shares the origin story of XCancer—born out of a desire to bring cutting-edge prostate cancer trials to community care settings—and how it has grown into a nationwide clinical research network supporting over 45 communit...

On this episode, hosts Scott and Sarah are joined by Matt Furlow, Associate Principal at ZS, about the evolving role of radiopharmaceuticals in oncology. With a PhD in bioengineering and a decade of consulting experience, Matt brings a unique perspective on how scientific insight and strategic planning intersect to help biotech and pharma companies bring new therapies to the market. Matt shares ho...

On this episode, hosts Scott and Sarah sit down with Dr. Suzanne Lapi, Professor of Radiology and Chemistry and Cyclotron Facility Director at the University of Alabama at Birmingham. The conversation dives into Dr. Lapi’s multifaceted role in radiopharmaceutical research, isotope production, and academic training. She shares how her team at UAB develops and ships radioisotopes globally, advances...

On this episode of Talk Radioisotopes, Scott and Sarah are joined by Dr. Shamar Young, Chief Medical Officer at TeleDaaS and Division Chief of Interventional Radiology at the University of Arizona. The discussion explores Dr. Young’s journey into interventional radiology, his expertise in Yttrium-90 (Y90) therapy, and the evolving role of precision dosimetry in radiopharmaceutical treatments. He h...

In this episode of Talk Radioisotopes, hosts Scott and Sarah welcome Bruno Paquin, CEO of AtomVie Global Radiopharma. Bruno delves into the complexities and advancements of the radiopharmaceutical industry. The discussion highlights AtomVie’s role as a leading contract development and manufacturing organization (CDMO), their cutting-edge work in cancer care, and the innovative new facility being b...

On this episode of Talk Radioisotopes, hosts Scott Larrivee and Sarah Scouten interview Arjun Murthy, co-founder of Maven Bio, an AI-driven biopharma market intelligence platform.  They explore how Arjun's background, along with Maven Bio's technology, is transforming data analysis and research in the biopharma sector. Key topics include how AI is aiding radiopharmaceutical research, the importanc...

On this episode, hosts Scott and Sarah sit down with Shaemus Gleason, Executive Vice President at Clarity Pharmaceuticals. The discussion highlights Shaemus's journey through the radiopharmaceutical industry, Clarity's innovations, and breakthroughs involving copper-based compounds for cancer treatment.  Shaemus shares insights on the importance of chelators, supply chain logistics, and diagnostic...

On our first episode of ‘Talk Radioisotopes: Going Nuclear on Cancer,' host Scott Larrivee is joined by co-host Dr. Sarah Scouten and guest Jeff Jones of Oppenheimer & Company. The discussion covers the latest trends in the radiopharmaceutical and radiotherapeutics markets, including the rise of targeted radiotherapies, the involvement of large pharmaceutical companies, and key developments in iso...

Radioisotopes are revolutionizing how cancers are detected and treated. But how do they work? And where is this field headed?  Whether you’re a healthcare professional, researcher, pharma exec, or industry analyst, this podcast is a go-to resource for the rapidly evolving radiopharmaceuticals landscape. Welcome to Talk Radioisotopes: Going Nuclear on Cancer. We’ll take a look at the latest insight...